Back to Agenda
Community Discussion of Data Science in Relation to Drug Development
Session Chair(s)
Ruthie Davi, PhD, MS
Vice President, Data Science and Statistician
Medidata, a Dassault Systèmes Company, United States
Stella C. Grosser, PhD, MS
Division Director, Office of Biostatistics, OTS, CDER
FDA, United States
This will be a community discussion of data science. Several panelists with experience in the area will be available to share their knowledge.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify common issues in the overlap between data science, statistics, and drug development
- Describe examples where data science has impacted pharmaceuticals
- Identify techniques of data science to possibly improve the efficiency of drug development
Speaker(s)
Speaker
Nareen Katta, MBA, MS
AbbVie, United States
Head of Data Science & Analytics
![Paul Schuette, PhD, MA](/_Images/member/Generic_Image_Missing-Profile.jpg)
Panelist
Paul Schuette, PhD, MA
FDA, United States
Mathematical Statistician, Scientific Computing Coordinator
![Matthew Austin, MS](/_Images/member/Generic_Image_Missing-Profile.jpg)
Speaker
Matthew Austin, MS
Amgen, United States
Executive Director, Data Science
Panelist
Joan Buenconsejo, PhD, MPH
Bristol Myers Squibb, United States
Head of Cardiovascular and Neuroscience Biostatistics
Have an account?